drugset / Trial / NCT00060996

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996

Phase 3 Terminated 30 enrolled United Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.

Timeline

Start
2003-02
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified Subcutaneous